Stock Events

Stock Events

Xilio Therapeutics 

$8.41
0
-$0.12-1.41% Today

Statistics

Day High
8.41
Day Low
8.41
52W High
-
52W Low
-
Volume
3
Avg. Volume
-
Mkt Cap
441.53M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Next
-1.54
-1.18
-0.81
-0.45
Expected EPS
-0.66
Actual EPS
N/A

Financials

-918.05%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
12.69MRevenue
-116.48MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XLO.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that develops medications in oncology, competing directly with Xilio's cancer therapy focus.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb operates in the biopharmaceutical industry, focusing on cancer treatments, which aligns with Xilio's therapeutic areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio including oncology, directly competing with Xilio's cancer-focused therapies.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG specializes in biotechnology products for oncology, making it a direct competitor in the cancer treatment market.
Novartis
NVS
Mkt Cap237.61B
Novartis AG focuses on innovative medicines, including oncology, which competes with Xilio's cancer therapy developments.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is a biotech company with a strong focus on oncology, competing in the same therapeutic area as Xilio.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is involved in the discovery, development, and commercialization of innovative therapeutics in areas including oncology.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biopharmaceuticals, including cancer treatments, making it a competitor.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC is a global, science-led biopharmaceutical business that focuses on oncology, among other areas, competing with Xilio.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson operates in the pharmaceuticals sector with a broad range of products, including oncology, competing with Xilio's focus.

About

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
ISIN
US98422T1007

Listings

XNAS
US
XLO
BOATS
BOATS
XLO.BOATS

0 Comments

Share your thoughts

FAQ

What is Xilio Therapeutics stock price today?▼
The current price of XLO.BOATS is $8.41 USD — it has decreased by -1.41% in the past 24 hours. Watch Xilio Therapeutics stock price performance more closely on the chart.
What is Xilio Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xilio Therapeutics stocks are traded under the ticker XLO.BOATS.
What is Xilio Therapeutics market cap?▼
Today Xilio Therapeutics has the market capitalization of 441.53M
When is the next Xilio Therapeutics earnings date?▼
Xilio Therapeutics is going to release the next earnings report on May 07, 2026.
What were Xilio Therapeutics earnings last quarter?▼
XLO.BOATS earnings for the last quarter are -1.54 USD per share, whereas the estimation was -0.45 USD resulting in a -244.83% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Xilio Therapeutics revenue for the last year?▼
Xilio Therapeutics revenue for the last year amounts to 12.69M USD.
What is Xilio Therapeutics net income for the last year?▼
XLO.BOATS net income for the last year is -116.48M USD.
When did Xilio Therapeutics complete a stock split?▼
The last stock split for Xilio Therapeutics was on March 16, 2026 with a ratio of 1:14.